...
首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Novel Gene Silencer Pyrrole-Imidazole Polyamide Targeting Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Attenuates Restenosis of the Artery After Injury
【24h】

Novel Gene Silencer Pyrrole-Imidazole Polyamide Targeting Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Attenuates Restenosis of the Artery After Injury

机译:靶向凝集素样氧化的低密度脂蛋白受体1的新型基因沉默子吡咯-咪唑聚酰胺可减轻损伤后的动脉再狭窄。

获取原文

摘要

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a membrane protein that can support the binding, internalization, and proteolytic degradation of oxidized low-density lipoprotein. The LOX-1 expression increases in the neointima after balloon injury. To develop an efficient compound to inhibit LOX-1, we designed and synthesized a novel gene silencer pyrrole-imidazole (PI) polyamide targeting the rat LOX-1 gene promoter (PI polyamide to LOX-1) to the activator protein-1 binding site. We examined the effects of PI polyamide to LOX-1 on the LOX-1 promoter activity, the expression of LOX-1 mRNA and protein, and neointimal hyperplasia of the rat carotid artery after balloon injury. PI polyamide to LOX-1 significantly inhibited the rat LOX-1 promoter activity and decreased the expression of LOX-1 mRNA and protein. After balloon injury of the arteries, PI polyamide to LOX-1 was incubated for 10 minutes. Fluorescein isothiocyanate–labeled PI polyamide was distributed to almost all of the nuclei in the injured artery. PI polyamide to LOX-1 (100 μg) significantly inhibited the neointimal thickening by 58%. PI polyamide preserved the re-endothelialization in the injured artery. PI polyamide significantly inhibited the expression of LOX-1, monocyte chemoattractant protein-1, intercellular adhesion molecule-1, and matrix metalloproteinase-9 mRNAs in the injured artery. The synthetic PI polyamide to LOX-1 decreased the expression of LOX-1 and inhibited neointimal hyperplasia after arterial injury. This novel gene silencer PI polyamide to LOX-1 is, therefore, considered to be a feasible agent for the treatment of in-stent restenosis.
机译:凝集素样氧化型低密度脂蛋白受体-1(LOX-1)是一种膜蛋白,可支持氧化型低密度脂蛋白的结合,内化和蛋白水解降解。球囊损伤后新内膜的LOX-1表达增加。为了开发抑制LOX-1的有效化合物,我们设计并合成了一种新型基因沉默剂吡咯-咪唑(PI)聚酰胺,将大鼠LOX-1基因启动子(PI聚酰胺连接至LOX-1)靶向激活剂蛋白-1结合位点。我们检查了PI聚酰胺对LOX-1的影响,对LOX-1启动子活性,LOX-1 mRNA和蛋白的表达以及大鼠颈动脉球囊损伤后内膜增生的影响。 PI聚酰胺对LOX-1的抑制显着抑制了大鼠LOX-1启动子的活性,并降低了LOX-1 mRNA和蛋白的表达。动脉球囊损伤后,将LOX-1的PI聚酰胺孵育10分钟。异硫氰酸荧光素标记的PI聚酰胺几乎分布在受伤动脉的几乎所有核中。 PI聚酰胺对LOX-1(100μg)的抑制作用最大为抑制了58%的新内膜增厚。 PI聚酰胺保留了受伤动脉的再内皮化作用。 PI聚酰胺显着抑制了受损动脉中LOX-1,单核细胞趋化蛋白1,细胞间粘附分子1和基质金属蛋白酶9 mRNA的表达。合成的LOX-1的PI聚酰胺降低了LOX-1的表达并抑制了动脉损伤后的内膜增生。因此,LOX-1的这种新型基因沉默PI聚酰胺被认为是治疗支架内再狭窄的可行药物。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号